Wallonia

©IBA

Where nuclear medicine radiates



BioWin, at the heart of an innovative ecosystem

"BioWin helps us to get access to research & development aid in the form of subsidies but also facilitates our communication with the Walloon Region or other players in the nuclear medicine field. We also appreciate BioWin's support in the setup of R&D projects, thus encouraging reflection on their impact and the justification of these projects."

Gauthier Philippart CEO Trasis

"Telix is pleased to benefit from the radiopharmaceutical assets and skills that exist in Wallonia to develop its activities. It is an ideal environment to help us deliver the promise of nuclear medicine in targeted therapy and help even more patients to cure and treat their cancer."



"Since the launch of our Gallium-68 generator in 2017, born from a Biowin R&D project, the need for this radioisotope used in cancer imaging has been continuously growing. We are one of the two providers of Gallium-68 serving the global market. Thanks to the BioWin network, we have entered into several partnerships such as with Trasis, another BioWin member. Another major advantage BioWin offers is the call for collaborative R&I projects that allows us to work with the academic world and other partners to develop new innovative and differentiating solutions for our customers."

Bérénice Pignol

Head of Marketing & Communication IRE ELIT

"We from ABSCINT are very happy to be part of the Walloon ecosystem around radiopharma activities. The fact that other companies such as Trasis, ANMI, Nucleis,... are in our immediate vicinity is a big advantage. We can consult with them and set up collaborations.

BioWin has certainly helped us to become part of the Walloon network and the BioWin people are always there to advise us when we are looking for a suitable partner. Without our BioWin partnership, it would be much more difficult to integrate into the ecosystem."

Karine Clauwaert

CEO Abscint

Radiation applications in healthcare in Wallonia

AN INTEGRATED VALUE CHAIN AND A WORLD-RENOWNED ECOSYSTEM

- Radionuclide production for worldwide use and development activities for new radionuclides, radiation protection and radioactive waste handling.
- Connects national and international networks dedicated to **nuclear applications** in healthcare.
- Unique partnerships for the production of **key radioisotopes**: 68Ga, 99Mo, 177Lu, 225Ac.
- Manufacturing **radiopharmaceutical products** with the development of generators, cold kits or injection solutions, and turnkey solutions for radiopharmacies.
- Strong network of expertise to complete the whole value chain in software solutions, regulatory framework, intellectual property and market studies.
- Cyclotron manufacturing and proton therapy solutions.



A DYNAMIC AND MATURE ECOSYSTEM TO HELP YOU DEVELOP YOUR PRODUCTS & SERVICES



Multiple **R&D programs** within universities in coordination with public and private R&D centers and hospitals.



R&D activities with **imaging** and services developed to conduct **preclinical and clinical research up to phase III.**



Training programs covering the entire value chain (GMP concepts, nuclear safety, clinical trials, transport, regulatory, etc.).

BELGIUM: Internationally recognized for its significant role in nuclear medicine

- One of the five global players in the production and distribution of medical radioisotopes.
- One in three hospitals in the world specializing in nuclear medicine uses Belgian technology.
- Nearly 7 million patients undergo medical examinations every year thanks to Belgian production of ⁹⁹Mo.



View all our active projects in nuclear medicine here





The health competitiveness cluster of Wallonia

Serving health biotech and medtech innovation

Founded in 2006 to:

- Unify innovative life science players in Wallonia.
- · Create a positive impact on society via health innovation.
- · Showcase Wallonia as a world-class life science research environment.

BioWin represents more than 90% of the health biotech and medtech players in Wallonia in a diverse and growing ecosystem of more than 250 active members.



Your contact at BioWin Marianne Ghyoot Director Research & Innovation marianne.ghyoot@biowin.org



Entry point for medical device and digital health in Wallonia

Our partners: OGIO CAPITAL KEYRUS



biowin.org in ¥f ⊡

Visit our website & follow the latest member news

With the support of:





Companies in radiation applications in healthcare & related activities

Click on the logos to visit the company website.

	Clinical stage molecular imaging company that develops in-vivo diagnostics based on single domain antibodies.	
Contraction of the second seco	Development, manufacturing and marketing of clinical diagnostic products for RIA and ELISA applications in the field of endocrinology, auto-immunity and infectious diseases.	
	Design, manufacturing, and installation of solutions for radiation protection and quality control in radio-pharmacy and nuclear medicine.	elysia 🖉 raytest
ва	IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,600 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.	
	Production of radioisotopes & radiopharmaceuticals for diagnosis and therapy in nuclear medicine. World's leader in Molybdenum-99 production, the 'parent' isotope of Technetium-99, the most used isotope in nuclear medicine for many examinations.	iR≡
	GMP company focusing on manufacturing of PET tracers under Marketing Authorization and for clinical trials.	
	Design, development and manufacturing of multi-purpose radiochemistry synthesizers based on an open platform for the production of radiopharmaceuticals.	NEPTIS
()) Telix	Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic ('theranostic') products using molecularly targeted radiation (MTR).	
	Trasis designs, develops, produces and markets comprehensive solutions to manufacture, control, dispense and administrate radiopharmaceuticals.Our solutions, including automates, raw materials and customers support, allow industry, research centers and hospitals to push the limits of Nuclear Medicine worldwide.Trasis focus its ressources to accelerate the availability on the market of innovative diagnostics and treatments to fight effectively against cancers and neurodegenerative diseases.	TRASIS
	Radiomics is an Al-powered research organisation providing image-based insights to support clinical trial and research design making. Radiomics optimises pharmaceutical and biotech companies' clinical trials and drug development trajectories through advanced image analysis technology and by providing decision support tools to clinicians to ensure that patients can benefit from a personalised medicine approach that enables them to receive the best possible treatment.	



Research laboratories in radiation applications in healthcare

Click on the logos to visit the company website.

UCLouvain	Preclinical and clinical research in oncology, cardiology and neurology. Molecular imaging and radiotherapy. PET and SPECT/CT systems.	
	Research and clinical imaging, mainly for neurosciences, secondarily for all clinical domains including oncology and immunology. Production of most radiotracers routinely used in clinical PET.	ULB
LIÈGE université	Synthesis of radiopharmaceuticals. Preclinical and clinical research with PET and MRI in neuroscience, oncology and cardiology.	
	Accelerator technology and targetry, radioisotope production by accelerator, nuclear reaction analysis, Monte-Carlo Simulation of particle and photon interaction with living or non-living matter, radioprotection, hadron and photon radiobiology, life science application of nanoparticles.	UNIVERSITË
Université de Mons	Development, synthesis and characterization of radiosensitizing nanoparticles traceable with MRI. Development of nanoparticle-based bimodal PET/MRI probes. Preparation of specific chelates for SPECT or PET imaging. Study of the effects of proton therapy in upper aerodigestive tract cancers (in vitro, in-vivo and clinical study).	
	Molecular imaging in clinical and translational research in oncology. Development and clinical implementation of new targeted radionuclide treatments and new radiation approaches for patients.	JULES BORDET
	Integrated preclinical imaging facility which provides services and training for academic and industrial partners.	

